Can Chinese Medicine Be Used for Prevention of Corona Virus Disease 2019 (COVID-19)? A Review of Historical Classics, Research Evidence and Current Prevention Programs

Hui Luo, Qiao-Ling Tang, Ya-Xi Shang, Shi-Bing Liang, Ming Yang, Nicola Robinson, Jian-Ping Liu, Hui Luo, Qiao-Ling Tang, Ya-Xi Shang, Shi-Bing Liang, Ming Yang, Nicola Robinson, Jian-Ping Liu

Abstract

Objective: Since December 2019, an outbreak of corona virus disease 2019 (COVID-19) occurred in Wuhan, and rapidly spread to almost all parts of China. This was followed by prevention programs recommending Chinese medicine (CM) for the prevention. In order to provide evidence for CM recommendations, we reviewed ancient classics and human studies.

Methods: Historical records on prevention and treatment of infections in CM classics, clinical evidence of CM on the prevention of severe acute respiratory syndrome (SARS) and H1N1 influenza, and CM prevention programs issued by health authorities in China since the COVID-19 outbreak were retrieved from different databases and websites till 12 February, 2020. Research evidence included data from clinical trials, cohort or other population studies using CM for preventing contagious respiratory virus diseases.

Results: The use of CM to prevent epidemics of infectious diseases was traced back to ancient Chinese practice cited in Huangdi's Internal Classic (Huang Di Nei Jing) where preventive effects were recorded. There were 3 studies using CM for prevention of SARS and 4 studies for H1N1 influenza. None of the participants who took CM contracted SARS in the 3 studies. The infection rate of H1N1 influenza in the CM group was significantly lower than the non-CM group (relative risk 0.36, 95% confidence interval 0.24-0.52; n=4). For prevention of COVID-19, 23 provinces in China issued CM programs. The main principles of CM use were to tonify qi to protect from external pathogens, disperse wind and discharge heat, and resolve dampness. The most frequently used herbs included Radix astragali (Huangqi), Radix glycyrrhizae (Gancao), Radix saposhnikoviae (Fangfeng), Rhizoma Atractylodis Macrocephalae (Baizhu), Lonicerae Japonicae Flos (Jinyinhua), and Fructus forsythia (Lianqiao).

Conclusions: Based on historical records and human evidence of SARS and H1N1 influenza prevention, Chinese herbal formula could be an alternative approach for prevention of COVID-19 in high-risk population. Prospective, rigorous population studies are warranted to confirm the potential preventive effect of CM.

Keywords: Chinese medicine; clinical evidence; corona virus disease 2019 (COVID-19); prevention program; review.

Conflict of interest statement

The authors declare that they have no competing interest.

References

    1. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Lancet. 2020. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.
    1. National Health Commission of the People’s Republic of China. Feb 12: Daily briefing on novel coronavirus cases in China. 2020.
    1. World Health Organization. Novel coronavirus (2019-nCoV) situation report 22. 2020.
    1. Wang C H, P W H, F G, Gao F. Lancet. 2020. A novel coronavirus outbreak of global health concern.
    1. National Health Commission of the People’s Republic of China. Announcement of the National Health Commission of the People’s Republic of China (No. 1 in 2020). 2020/1/20. 2020.
    1. World Health Organization. Q&A on coronaviruses. 2020/2/2. 2020.
    1. Wang, W Y, Yang J. An overview of the thoughts and methods of epidemic prevention in ancient Chinese Medicine. Jilin J Tradit Chin Med (Chin) 2011;31:197–199.
    1. Joseph N, Lu G. Hygiene and preventive medicine in ancient China. J History Med All Sci. 1962;17:429–478.
    1. Liu J, Manheimer E, Shi Y, Gluud C. Chinese herbal medicine for severe acute respiratory syndrome: a systematic review and meta-analysis. J Altern Complement Med. 2004;10:1041–1051. doi: 10.1089/acm.2004.10.1041.
    1. World Health Organization. SARS: clinical trials on treatment using a combination of traditional Chinese medicine and Western medicine. Geneva: Switzerland; 2004.
    1. National Administration of Traditional Chinese Medicine. Prevention program of traditional Chinese medicine for 2009 H1N1 influenza. Chin Comm Doctors (Chin) 2009;25:13.
    1. Su Y, Chen M. A brief analysis on the understanding of pestilence in Huangdi’s Internal Classic. J Pract Tradit Chin Med (Chin) 2005;21:508–509.
    1. Yuan Y. Therapeutic thoughts and academic contributions of 13 formulas in Huangdi’s Internal Classic. J Chengdu Univ Tradit Chin Med (Chin) 1990;13:46–48.
    1. Cheng K, Leung P. What happened in China during the 1918 influenza pandemic? Int J Infect Dis. 2007;11:360–364. doi: 10.1016/j.ijid.2006.07.009.
    1. Zhong Y, Yang J. Epidemic disease prevention in traditional Chinese medicine. J Nanjing Tradit Chin Med Univ (Chin) 2011;27:209–212.
    1. Sun SM Tang Dynasity. Essential prescriptions worth a thousand gold for emergencies (Bei Ji Qian Jin Yao Fang) Beijing: China Medical Science and Technology Press; 2011.
    1. Yao W. Finishing and Research of Plague Preventing between Jin and Tang Dynasties and the Ming and Qing Dynasties [dissertaion] Chengdu, China: Chengdu University of Traditional Chinese Medicine; 2009.
    1. Pang AS Song Dynasity. General treatise on febrile diseases (Shang Han Zong Bing Lun) Beijing: People’s Medical Publishing House; 2007.
    1. Lau J, Leung P, Wong E, Fong C, Cheng K, Zhang S, et al. The use of an herbal formula by hospital care workers during the severe acute respiratory syndrome epidemic in Hong Kong to prevent severe acute respiratory. J Alternat Complement Med. 2005;11:49–55. doi: 10.1089/acm.2005.11.49.
    1. Xu J, Jiang X, Liu F, Zhang W. Beijing. 2006. Clinical observation of Yinhua Yupingfeng Decoction in preventing SARS: analysis of 163 first-line medical staff. Conference on the prevention and treatment of SARS in integrated traditional Chinese and Western medicine in five provinces of North China; pp. 158–159.
    1. Zhang L, Chen B, Zeng H. Analysis of fangdu decoction on SARS and zero infection in hospital. Chin J Hosp Pharm (Chin) 2005;25:59–60.
    1. Song Y, Wang X, Xue J, Gao K, Liang H, Liu L, et al. Clinical observation of prevention of influenza A (H1N1) by Qingjie Fanggan Granules. Shaanxi J Tradit Chin Med (Chin) 2019;40:886–889.
    1. Liu L, Xu G, Xu X, Xia F, Pei X, Cui S, et al. Preliminary observation on the prevention of influenza A (H1N1) by the formula of Jialiu Yufang Formula. Beijing J Tradit Chin Med (Chin) 2013;32:91–92.
    1. Xia B, Shi J, Jia N, Wang H, Zhang X. Effect of Kangbingdu Oral Liquid and Ganmaoqingre Granule on prevention of influenza A (H1N1) People’s Milit Surg (Chin) 2010;53:645–646.
    1. Liu B. Clinical observation on the prevention of influenza A H1N1 with the prevention theory of TCM. Tradit Chin Med Res (Chin) 2010;23:46–47.
    1. National Health Commission of the People’s Republic of China. Diagnosis and treatment of pneumonia caused by the 2019 new coronavirus (2019-nCoV) 2020.
    1. Du C, Zheng K, Bi C, Dong T, Lin H, Tsim K. Yu Ping Feng San, an ancient Chinese herbal decoction, induces gene expression of anti-viral proteins and inhibits neuraminidase activity. Phytother Res. 2015;29:656–661. doi: 10.1002/ptr.5290.
    1. Gao J, Li J, Shao X, Jin Y L X, Ge J, et al. Antiinflammatory and immunoregulatory effects of total glucosides of Yupingfeng Powder. Chin Med J. 2009;122:1636–1641.
    1. Wang C, Cao B, Liu Q, Zou Z, Liang Z, Gu L, et al. Oseltamivir compared with the Chinese traditional therapy Maxingshigan-Yinqiaosan in the treatment of H1N1 Influenzaa randomized trial. Ann Intern Med. 2011;155:217–225. doi: 10.7326/0003-4819-155-4-201108160-00005.
    1. Liu L, Lei N, Lin Q, Wang L, Yan H, Duan X. The effects and mechanism of Yinqiao Powder on upper respiratory tract infection. Int J Biotech Wellness Indust. 2015;4:57–60. doi: 10.6000/1927-3037.2015.04.02.2.
    1. Chen M. Theoretical study of three factors-concerned treatment [dissertaion] Jinan: Shandong University of Traditional Chinese Medicine; 2013.
    1. Ou AH, Lu CJ, Li JQ, Li XY, Wen ZH, Deng H, et al. Analysis on the Chinese medicine syndromes and demographic characteristics of patients with influenza-like illness in clinics of China. Chin J Integr Med. 2014;20:101–106. doi: 10.1007/s11655-013-1582-8.
    1. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. JAMA. 2020. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China.
    1. Gao Y, Liu QY. The epidemic dynamics of 2019 novel coronavirus (2019-nCoV) infections in China by 28 January. 2020/1/29. 2020.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj